Who are Lqttrx's investors?

Lqttrx's investors include Amzak Health, adMare BioInnovations, Alexandria, CTI Life Sciences Fund L.P., Lumira Ventures.

Lqttrx

Founded 2019 · 34 employees on LinkedIn · 5 known investors

Find your way into Lqttrx

Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases. Its lead compound, THRV-1268, is in a Phase 2/3 clinical study for Long QT Syndrome Type 2.

Biotech Healthtech Medical Devices

Founders & leadership

Paul F. TruexinChairman of the Board & Chief Executive OfficerChairman of the Board & Chief Executive Officer at Thryvtrx

Debra OdinkinPresident & Chief Development Officer at Thryvtrx

Amy SehnertinChief Medical Officer at Thryvtrx

Investors · 5

Amzak Health✓ verifiedNew York

adMare BioInnovations✓ verifiedVancouver

Alexandria✓ verifiedPasadena

CTI Life Sciences Fund L.P.✓ verifiedMontréal

Lumira Ventures✓ verifiedToronto · $1M – $10M

Frequently asked questions

What does Lqttrx do?: Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases. Its lead compound, THRV-1268, is in a Phase 2/3 clinical study for Long QT Syndrome Type 2.
Who are Lqttrx's investors?: Lqttrx's investors include Amzak Health, adMare BioInnovations, Alexandria, CTI Life Sciences Fund L.P., Lumira Ventures.